Kathy Boltz, PhD

Most Recent Articles by Kathy Boltz, PhD

Classifying gene mutations in neuroblastoma may point to improved treatments

Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to the drugs that target these mutations.

BRCA-related tumors respond to olaparib

Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.

Biopsies overused in diagnosing lung cancer, according to Medicare cost analysis

Biopsies are the most costly tool associated with lung cancer diagnosis, according to research.

Risk stratification model aids lung cancer staging and treatment decisions

A risk stratification model, based on lymph node characteristics, can confirm a negative classification of lung cancer with a high level of confidence.

Oral cancers in different locations in smokers vs nonsmokers

The relatively high incidence of mouth squamous cell cancer in nonsmokers without obvious causes has been noted in studies, with nonsmokers having a higher proportion of cancers occur on the edge of the tongue.

More Articles by Kathy Boltz, PhD

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs